menu
    • menu

    Company profile for Genexine

    NEW Drugs in Dev: 18
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Genexine is a clinical stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next generation novel long-acting biologics. Our goal is to bring to patients medicines that will transform their lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Genexinekorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    700 Daewangpangyo-ro, Korea Bio Park Bldg. B, Bundang-gu, Seongnam-si, Gyeongg...
    Telephone
    Telephone
    +82 31 628 3200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.genexine.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/genexine-inc-
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Egret Therapeutics Inks MoU for Full GX-P1 (PD-1) Ownership
    Egret Therapeutics Inks MoU for Full GX-P1 (PD-1) Ownership

    16 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/egret-therapeutics-signs-memorandum-of-understanding-with-genexine-toward-full-ownership-of-lead-pd-1-agonist-asset-gx-p1-egt-101-302714951.html

    PR NEWSWIRE
    16 Mar 2026
    Share Share
    Genexine Merges With EPD Biotherapeutics To Boost Drug Pipeline
    Genexine Merges With EPD Biotherapeutics To Boost Drug Pipeline

    04 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240704945037/en

    BUSINESSWIRE
    04 Jul 2024
    Share Share
    Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
    Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)

    23 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231022313600/en

    BUSINESSWIRE
    23 Oct 2023
    Share Share
    Genexine's weekly growth hormone equal to Novo shot in phase 3
    Genexine's weekly growth hormone equal to Novo shot in phase 3

    31 Aug 2023

    // Nick Paul Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/genexines-weekly-growth-hormone-equal-novo-shot-phase-3-teeing-filing-china

    Nick Paul Taylor FIERCE BIOTECH
    31 Aug 2023
    Share Share
    Genexine Abstract on GX-188E and GX-I7 Therapy in HNSCC Is Released
    Genexine Abstract on GX-188E and GX-I7 Therapy in HNSCC Is Released

    26 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230525005928/en

    BUSINESSWIRE
    26 May 2023
    Share Share
    Genexine says long-acting anaemia therapy succeeds against Roche, CSL's Mircera
    Genexine says long-acting anaemia therapy succeeds against Roche, CSL's Mircera

    12 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230411005535/en/Genexine%E2%80%99s-Long-acting-Anemia-Treatment-GX-E4-Phase-3-Clinical-Trial-Interim-Result-Is-Presented-at-WCN2023-Confirmed-Non-inferiority-Compared-to-Mircera

    BUSINESSWIRE
    12 Apr 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search